<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398370</url>
  </required_header>
  <id_info>
    <org_study_id>PMD-MSC-ED-01</org_study_id>
    <nct_id>NCT02398370</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of Mild to Moderate ED</brief_title>
  <acronym>PMD-MSC-ED-01</acronym>
  <official_title>Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Mild to Moderate Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melissa Marchand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Z Urology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open-label, non-randomized, study to be conducted at a single center. Ten&#xD;
      subjects will undergo an injection of Placental Matrix-Derived Mesenchymal Stem Cells&#xD;
      (PMD-MSCs) into the penis for the treatment of mild to moderate erectile dysfunction. Follow&#xD;
      up visits will be conducted at 6 weeks, 3 months, 6 months, and 12 months. Subjects will be&#xD;
      evaluated for re-injection beginning at 3 months. Eligibility is determined by the clinician&#xD;
      based on patient reported treatment satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 18 million men in the United States are diagnosed with Erectile Dysfunction&#xD;
      (ED). ED is a physical condition triggered by a man's mental, emotional, and medical state.&#xD;
      Defined by the repeated and consistent problem sustaining an erection suitable for sexual&#xD;
      intercourse; ED can lead to performance anxiety and depression as a result partners of men&#xD;
      with ED also suffer emotional and psychological effects.&#xD;
&#xD;
      Lifestyle, smoking, medical conditions such as diabetes, hypertension and vascular problems,&#xD;
      prostate cancer and medication side effects all can contribute to the cause of ED.&#xD;
&#xD;
      Conservative treatments can begin with lifestyle change; natural remedies include the use of&#xD;
      herbs such as L-Arginine, Ginko, Zinc, and Yohimbe. Prescription medications known as&#xD;
      phosphodiesterase type 5 inhibitors are often used but are costly. other therapies involve&#xD;
      the penis pump/penis vacuum, penile implants that offer a permanent solution and surgery to&#xD;
      improve the blood flow to the penis can improve erections.&#xD;
&#xD;
      Mesenchymal stem cells (MSCs) have been used for a variety of medical treatments to repair&#xD;
      and regenerate acute and chronically damaged tissues. These cells have the potential to&#xD;
      repair human tissue by forming cells of mesenchymal origin, such as cartilage, bone, fat,&#xD;
      muscle, and blood vessels. Most research has focused on bone marrow derived stem cells (BMC)&#xD;
      however the process for harvesting the cells is invasive, painful, and yields a low cell&#xD;
      count. The human placenta offers an alternative source form MSCs. Placental Matrix-Derived&#xD;
      Mesenchymal Stem Cells (PMD-MSCs) are compromised of a novel cellular repair matrix derived&#xD;
      from placental mesenchyme. Mesenchyme is the meshwork of embryonic connective tissue in the&#xD;
      mesoderm, from which are formed the muscular and connective tissues of the body and also the&#xD;
      blood vessels. PMD-MSCs provide the extracellular matrix viable mesenchymal stem cells (MSCs)&#xD;
      that coordinate the tissue repair process, regenerative growth factors, and anti-inflammatory&#xD;
      cytokines required to regenerate the damaged vasculature of the penile corpora.&#xD;
&#xD;
      Injecting PMD-MSCs into the penile corpora to replace the dysfunctional or dead cells is an&#xD;
      intriguing option for cell-based treatment for ED. The research proposed here will establish&#xD;
      the safety and feasibility of utilizing intracavernosal injections of PMD-MSCs to treat&#xD;
      Erectile Dysfunction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Systolic Velocity without trimix (cm/s)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Systolic Velocity without trimix (cm/s)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Systolic Velocity without trimix (cm/s)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Systolic Velocity without trimix (cm/s)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Systolic Velocity without trimix (cm/s)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Velocity without trimix (cm/s)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Velocity without trimix (cm/s)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Velocity without trimix (cm/s)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Velocity without trimix (cm/s)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Velocity without trimix (cm/s)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak Systolic Velocity with trimix (cm/s)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Systolic Velocity with trimix (cm/s)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Systolic Velocity with trimix (cm/s)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Systolic Velocity with trimix (cm/s)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Systolic Velocity with trimix (cm/s)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>End Diastolic Velocity with trimix (cm/s)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>End Diastolic Velocity with trimix (cm/s)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>End Diastolic Velocity with trimix (cm/s)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>End Diastolic Velocity with trimix (cm/s)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>End Diastolic Velocity with trimix (cm/s)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rigidity test (Pass / Fail)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rigidity test (Pass / Fail)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rigidity test (Pass / Fail)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rigidity test (Pass / Fail)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rigidity test (Pass / Fail)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stretched Penile Length before trimix (cm/s)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stretched Penile Length before trimix (cm/s)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stretched Penile Length before trimix (cm/s)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stretched Penile Length before trimix (cm/s)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stretched Penile Length before trimix (cm/s)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Post Penile Width with trimix</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Post Penile Width with trimix</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Post Penile Width with trimix</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Post Penile Width with trimix</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Post Penile Width with trimix</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Injection of PMD-MSCs into the penis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based patient reported treatment satisfaction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)</intervention_name>
    <arm_group_label>Injection of PMD-MSCs into the penis</arm_group_label>
    <other_name>Ovation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men aged 40-70&#xD;
&#xD;
          2. Willing and able to provide written informed consent&#xD;
&#xD;
          3. Chronic, organic erectile dysfunction (ED), duration at least 0.5 years, with baseline&#xD;
             International Index of Erectile Function-Erectile Function (IIEF-EF) score greater&#xD;
             than or equal to 21&#xD;
&#xD;
          4. Willing to complete questionnaires&#xD;
&#xD;
          5. Involved in a monogamous, heterosexual relationship for at least 3 months with both&#xD;
             partners motivated to have or attempt sexual intercourse at least 4 times per month&#xD;
             beginning two weeks after study treatment (subject reported)&#xD;
&#xD;
          6. Not interested or able to use oral PDE-5 inhibitor (PDE-5i) drug therapy, and willing&#xD;
             to forgo these treatments for the first 6-month period following study treatment (in&#xD;
             addition may include a 4-week washout since last PDE-5i use prior to completion of the&#xD;
             baseline erectile function assessments and study treatment)&#xD;
&#xD;
          7. Willing to limit alcohol intake and eliminate use of recreational drugs for sexual&#xD;
             encounters&#xD;
&#xD;
          8. Willing to undergo an injection 9 Mentally competent and able to understand all study&#xD;
             requirements (based on investigator assessment)&#xD;
&#xD;
        10. Willing to be available for all baseline, treatment, and follow up examinations&#xD;
        required by protocol 11. Willing to forego participation in any other study throughout the&#xD;
        duration of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of prostate cancer which requires additional radiotherapy or other adjuvant&#xD;
             therapy&#xD;
&#xD;
          2. Previous pelvic or abdominal radiation therapy&#xD;
&#xD;
          3. Previous, concomitant or scheduled use of anti-androgen therapy&#xD;
&#xD;
          4. Untreated hypogonadism or low serum total testosterone (&lt;200 ng/dL)&#xD;
&#xD;
          5. Clinically evident penile anatomical deformities (e.g., Peyronie's disease) or history&#xD;
             of priapism&#xD;
&#xD;
          6. Skin irritation, infection, wound, sore, or disruption in the immediate areas of skin&#xD;
             entry for penile injection&#xD;
&#xD;
          7. Use of any non-study treatment for erectile dysfunction within 4 weeks of study&#xD;
             treatment and a lack of willingness to continue through 6 months after study treatment&#xD;
&#xD;
          8. Any previous penile implant or penile vascular surgery&#xD;
&#xD;
          9. Current or previous malignancy other than localized prostate cancer&#xD;
&#xD;
         10. Uncontrolled hypertension or hypotension (systolic blood pressure &gt; 170 or &lt;90 mm Hg,&#xD;
             and diastolic blood pressure &gt; 100 or &lt; 50 mm Hg)&#xD;
&#xD;
         11. Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction&#xD;
             within the past 6 months, cardiac failure or life-threatening arrhythmia, congestive&#xD;
             heart failure) or symptomatic postural hypotension within 6 months before screening&#xD;
&#xD;
         12. Current urinary tract or bladder infection&#xD;
&#xD;
         13. Drug, alcohol, or substance abuse reported within the last three years (subject&#xD;
             reported) Subject's sexual partner &lt; 18 years of age or has any gynecologic problems&#xD;
&#xD;
         14. Major medical conditions, or any other factors that would limit participation in&#xD;
             sexual intercourse to less than 4 times per month (subject reported)&#xD;
&#xD;
         15. Weight less than 154lbs/ 70 kg, or BMI greater than or equal to 30&#xD;
&#xD;
         16. Systemic autoimmune disorder&#xD;
&#xD;
         17. Significant active systemic or localized infection&#xD;
&#xD;
         18. Receiving immunosuppressant medications&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P. Zahalsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Z Urology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Z Urology</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Z Urology</investigator_affiliation>
    <investigator_full_name>Melissa Marchand</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>ED</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

